Avana Health

What Avana Health does

Avana Health, Inc. is a Delaware-incorporated, Raleigh-headquartered women's health company founded in 2021 that is developing drug-and-device combination treatments for two large unmet needs in uterine health: postpartum hemorrhage (PPH) and abnormal uterine bleeding (AUB). Its core technology is the proprietary HemmoStat system, invented by Dr. John Morehead, a board-certified OB/GYN with 38 years of clinical experience. The HemmoStat platform pairs a drug with anticipated onset under three minutes that produces rapid local cessation of blood flow and does not require refrigeration, with a single-use sterile device that creates a water-tight seal, delivers optimal drug pressure, and incorporates quantitative blood-loss measurement. Two product candidates are in development: HemmoStat PPH, positioned to complement standard-of-care pharmacologic treatments and reduce reliance on surgical interventions for the leading global cause of maternal mortality, and HemmoStat AUB, a fast outpatient procedure targeting a condition that drives 33 million U.S. cases per year, one-third of gynecologist visits, and 5% of emergency room visits, and for which no FDA-approved acute management solution currently exists. Both candidates are designed to be fertility-preserving.

The company is pre-revenue and is operating in clinical-stage mode, having commenced first clinical trials in the 2022-2025 period. It is led by CEO Peter Pacult (20 years of life-sciences operational and drug development experience), with founder Dr. John Morehead as President/CTO, Michael Royals (translational medicine specialist) as CSO, Howard Settle (long-tenured angel investor and CFO), and Angela Morehead as Research Director. Avana has assembled a credentialed advisory bench including former Pfizer and Sanofi clinical research executives, a UCLA/FIGO Menstrual Disorders Committee chair, a former FDA CDRH Senior Science Health Advisor, and an OSU maternal-fetal medicine specialist, alongside a CDMO partnership with Gilero for device design and manufacturing and regulatory support from The Gnomon Group. Capitalization is angel- and founder-led, with SEC Form D filings indicating a cumulative raise well under $5M and a December 2025 exempt offering of up to $4M. Distribution, pricing, and commercialization have not been established; the stated intent is to obtain approval from stringent national regulatory authorities and pursue an expedited pathway before global launch.

Name

Avana Health

Legal name

Avana Health, Inc.

Website

https://avana.health

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Avana Health is a pre-revenue, clinical-stage women's health company developing the HemmoStat drug-and-device system to treat postpartum hemorrhage and abnormal uterine bleeding, two indications with large unmet needs and no FDA-approved acute AUB solution.

Ownership category

akta.pro rank

Product category

Women's Health Therapeutics

NAICS

Offices of Physicians (62111)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Home Infusion Therapy & IV Nursing Services (HLADAFAG)

Keywords

• Women's health therapeutics
• Postpartum hemorrhage treatment
• Abnormal uterine bleeding treatment
• Drug-device combination products
• Maternal health medical devices

Headquarters

HQ city

Raleigh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-revenue / Clinical Stage: The company is currently in clinical trial phase and has not yet generated revenue. Seeking to raise $4 million through exempt offering of securities (per SEC Form D filing dated 2025-12-19). Prior funding round raised $127,500 of a planned $510,000 (per SEC Form D filing dated 2022-11-15).

Marketing channels3 records

Core offering

Avana Health is a clinical-stage women's health company developing the HemmoStat System, a drug-and-device combination treatment platform addressing abnormal uterine bleeding (AUB) and postpartum hemorrhage (PPH). The HemmoStat PPH Treatment System provides a fast-acting, non-surgical intervention intended to complement standard-of-care pharmacologic treatments, while the HemmoStat AUB Treatment System provides a fast outpatient procedure for acute management of abnormal uterine bleeding. Both products are designed for minimal provider training, single-use sterile use, no refrigerated storage, and fertility preservation.

Product overview

Avana Health is a women's health company developing a platform for uterine treatments. The company is developing two main treatment systems: a treatment for Abnormal Uterine Bleeding (AUB) and a treatment for Postpartum Hemorrhage (PPH). Both treatment systems consist of a drug and device kit. The platform is built on the proprietary HemmoStat System, invented by Dr. John Morehead. The treatments are designed as fast-acting, non-surgical interventions that aim to preserve fertility and complement standard-of-care pharmacologic treatments.

Differentiator

Problem solved

Functional benefit

Brands

• HemmoStat: The HemmoStat system is Avana Health's treatment system - a drug and device kit for treating postpartum hemorrhage and abnormal uterine bleeding. It was invented by Dr. John Morehead.

Products and services

• HemmoStat PPH Treatment System

Quantifiable outcome

• 33 million AUB cases per year in the US alone
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• The Gnomon GroupcoreImplementation/ SI/ Consulting PartnerRegulatory consulting partner providing support for pharmaceutical development. The Gnomon Group is a network of 15 regulatory consultants with over 200 years of combined experience. They have provided regulatory support for over 150 Investigative New Drug (IND) applications, including 15 compounds from early development to approved NDA. Expertise spans CMC, GMP, GLP, GCP, biostatistics, clinical operations, and project management.
• Fox RothschildminorImplementation/ SI/ Consulting PartnerNational law firm with 950 attorneys in 29 offices serving clients in more than 70 practice areas, including Intellectual Property, Corporate, Labor and Employment, Litigation and Real Estate. Deeply committed to diversity, equity, and inclusion.
• GilerocoreTechnology or IntegrationMedical device engineering partner providing design, development, and manufacturing services for medical devices, drug delivery systems, and combination products. Gilero is FDA registered, ISO 13485 certified and compliant with cGMPs. They work with trusted brands to design innovative products and accelerate device commercialization timelines.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Gynesonics: Developer of the Sonata system, a transcervical radiofrequency ablation platform for AUB associated with fibroids — overlapping AUB indication and OB/GYN adoption pathway with Avana's AUB treatment.
• Daré Bioscience: Clinical-stage women's health biopharmaceutical company advancing novel therapeutics in contraception, menopause, and uterine health. Comparable as an emerging clinical-stage peer pursuing women's reproductive health indications with novel mechanisms.

Broad incumbents

• Organon & Co. Global women's health-focused pharmaceutical company that acquired Alydia Health (Jada). Comparable as a broad incumbent targeting the same OB/GYN prescriber base and PPH/AUB clinical categories Avana addresses.
• Becton, Dickinson and Company (BD): BD markets the Bakri Postpartum Balloon, the current standard mechanical intervention for PPH. As the dominant incumbent device in the exact indication Avana targets, BD sets the competitive benchmark for both clinical practice and procurement.
• Hologic: Major women's health company with diagnostics, surgical, and device franchises (including MyoSure for AUB). Comparable as a broad incumbent selling into the same OB/GYN channel and addressing AUB-related procedures.
• CooperSurgical: Women's health and fertility device company with a broad OB/GYN portfolio including surgical instruments and assisted-reproductive products — comparable broad incumbent sharing Avana's clinical call point and fertility-preservation narrative.
• Bayer (Women's Health / Mirena franchise): Bayer's Mirena IUS and broader women's health portfolio address AUB management through hormonal therapy. Comparable as a broad incumbent shaping AUB standard-of-care against which Avana's non-hormonal device positioning must differentiate.

Direct peers

• Minerva Surgical: Commercial-stage company developing minimally invasive treatments for abnormal uterine bleeding, including the Minerva ES endometrial ablation system — a direct AUB-treatment peer competing for the same gynecologist call point as Avana.
• Alydia Health (Jada System, acquired by Organon): Alydia developed the Jada System, an intrauterine device that uses vacuum-induced tamponade to treat postpartum hemorrhage — a direct mechanistic peer to Avana's HemmoStat for the same PPH indication, now commercialized via Organon.
• InPress Technologies: Developer of a device-based postpartum hemorrhage treatment designed for rapid, low-skill administration — directly comparable to Avana's PPH system in indication, clinical workflow, and LMIC deployment thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avana Health